Literature DB >> 32347648

Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology.

Veli-Pekka Harjola1, John Parissis2, Johann Bauersachs3, Hans-Peter Brunner-La Rocca4, Hector Bueno5,6,7, Jelena Čelutkienė8, Ovidiu Chioncel9, Andrew J S Coats10, Sean P Collins11, Rudolf A de Boer12, Gerasimos Filippatos2, Etienne Gayat13, Loreena Hill14, Mika Laine15, Johan Lassus15, Jyri Lommi15, Josep Masip16,17, Alexandre Mebazaa13,18,19, Marco Metra20, Òscar Miró21, Andrea Mortara22, Christian Mueller23, Wilfried Mullens24, W Frank Peacock25, Markku Pentikäinen15, Massimo F Piepoli26, Effie Polyzogopoulou2, Alain Rudiger27, Frank Ruschitzka28, Petar Seferovic29, Alessandro Sionis30, John R Teerlink31, Thomas Thum32, Marjut Varpula15, Jean Marc Weinstein33,34, Mehmet B Yilmaz35.   

Abstract

Acute coronary syndrome is a precipitant of acute heart failure in a substantial proportion of cases, and the presence of both conditions is associated with a higher risk of short-term mortality compared to acute coronary syndrome alone. The diagnosis of acute coronary syndrome in the setting of acute heart failure can be challenging. Patients may present with atypical or absent chest pain, electrocardiograms can be confounded by pre-existing abnormalities, and cardiac biomarkers are frequently elevated in patients with chronic or acute heart failure, independently of acute coronary syndrome. It is important to distinguish transient or limited myocardial injury from primary myocardial infarction due to vascular events in patients presenting with acute heart failure. This paper outlines various clinical scenarios to help differentiate between these conditions and aims to provide clinicians with tools to aid in the recognition of acute coronary syndrome as a cause of acute heart failure. Interpretation of electrocardiogram and biomarker findings, and imaging techniques that may be helpful in the diagnostic work-up are described. Guidelines recommend an immediate invasive strategy for patients with acute heart failure and acute coronary syndrome, regardless of electrocardiographic or biomarker findings. Pharmacological management of patients with acute coronary syndrome and acute heart failure should follow guidelines for each of these syndromes, with priority given to time-sensitive therapies for both. Studies conducted specifically in patients with the combination of acute coronary syndrome and acute heart failure are needed to better define the management of these patients.
© 2020 European Society of Cardiology.

Entities:  

Keywords:  Acute coronary syndrome; Acute heart failure; Clinical scenario; Diagnosis; Management; Myocardial infarction; Myocardial injury; Troponins

Mesh:

Year:  2020        PMID: 32347648     DOI: 10.1002/ejhf.1831

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  12 in total

1.  Prevalence and prognostic importance of lung ultrasound findings in acute coronary syndrome: A systematic review.

Authors:  Moritz Lindner; Anika Lindsey; Paul A Bain; Elke Platz
Journal:  Echocardiography       Date:  2021-11-29       Impact factor: 1.724

2.  Evaluation of cardiometabolic risk markers linked to reduced left ventricular ejection fraction (LVEF) in patients with ST-elevation myocardial infarction (STEMI).

Authors:  Marjan Mahdavi-Roshan; Zeinab Ghorbani; Mahboobeh Gholipour; Arsalan Salari; Amir Savar Rakhsh; Jalal Kheirkhah
Journal:  BMC Cardiovasc Disord       Date:  2022-05-14       Impact factor: 2.174

3.  Targeting Circulating lncRNA ENST00000538705.1 Relieves Acute Coronary Syndrome via Modulating ALOX15.

Authors:  Hao Chen; Shiwei Huang; Fanlu Guan; Sisi Han; Fanhao Ye; Xun Li; Liyi You
Journal:  Dis Markers       Date:  2022-05-06       Impact factor: 3.464

4.  B-Lines by Lung Ultrasound Can Predict Worsening Heart Failure in Acute Myocardial Infarction During Hospitalization and Short-Term Follow-Up.

Authors:  Jiexin He; Shixin Yi; Yingling Zhou; Xiangming Hu; Ziheng Lun; Haojian Dong; Ying Zhang
Journal:  Front Cardiovasc Med       Date:  2022-05-02

5.  The Predictive role of Neutrophil-to-Lymphocyte Ratio (NLR) and Mean Platelet Volume-to-Lymphocyte Ratio (MPVLR) for Cardiovascular Events in Adult Patients with Acute Heart Failure.

Authors:  Teeranan Angkananard; Teeraporn Inthanoo; Suchat Sricholwattana; Nattapun Rattanajaruskul; Arthit Wongsoasu; Worawut Roongsangmanoon
Journal:  Mediators Inflamm       Date:  2021-10-11       Impact factor: 4.711

6.  Valosin Containing Protein as a Specific Biomarker for Predicting the Development of Acute Coronary Syndrome and Its Complication.

Authors:  Chenchao Xu; Bokang Yu; Xin Zhao; Xinyi Lin; Xinru Tang; Zheng Liu; Pan Gao; Junbo Ge; Shouyu Wang; Liliang Li
Journal:  Front Cardiovasc Med       Date:  2022-03-18

7.  The Role of Environmental PM2.5 in Admission Acute Heart Failure in ST-Elevation Myocardial Infarction patients - An Observational Retrospective Study.

Authors:  Andreja Sinkovic; Andrej Markota; Manja Krasevec; David Suran; Martin Marinsek
Journal:  Int J Gen Med       Date:  2021-11-18

Review 8.  A year in heart failure: an update of recent findings.

Authors:  Lorenzo Stretti; Dauphine Zippo; Andrew J S Coats; Markus S Anker; Stephan von Haehling; Marco Metra; Daniela Tomasoni
Journal:  ESC Heart Fail       Date:  2021-12-16

9.  Quality of Life Changes in Acute Coronary Syndromes Patients: A Systematic Review and Meta-Analysis.

Authors:  Billingsley Kaambwa; Hailay Abrha Gesesew; Matthew Horsfall; Derek Chew
Journal:  Int J Environ Res Public Health       Date:  2020-09-21       Impact factor: 3.390

10.  Clinical Characteristics and Predictors of In-Hospital Mortality among Older Patients with Acute Heart Failure.

Authors:  Giuseppe De Matteis; Marcello Covino; Maria Livia Burzo; Davide Antonio Della Polla; Francesco Franceschi; Alexandre Mebazaa; Giovanni Gambassi
Journal:  J Clin Med       Date:  2022-01-15       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.